Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Bridged-Ring Compounds
  • Neoplasm Recurrence, Local
  • Prostatic Neoplasms
  • Receptor, ErbB-2
  • Taxoids

abstract

  • Pertuzumab was well tolerated and resulted in no objective responses, but several patients had SD more than 23 weeks from a heavily pretreated population. Retrospective analysis suggested prolonged median survival time with pertuzumab compared with historical controls. Thus, inhibition of HER dimerization may have clinical utility in CRPC patients.

publication date

  • February 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.0649

PubMed ID

  • 17308272

Additional Document Info

start page

  • 675

end page

  • 81

volume

  • 25

number

  • 6